Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11594454 | 0.97 | LMNA (0.33) | LMNAHTTSMN1; SMN2CA1NPC1 | |
| SCHEMBL6825673 | 0.79 | — | — | |
| SCHEMBL41429 | 0.78 | CA1 (0.55) | LMNASMN1; SMN2CA1RAB9ACA12 | |
| SCHEMBL23617843 | 0.74 | — | — | |
| SCHEMBL10399036 | 0.74 | LMNA (0.33) | LMNAHTTSMN1; SMN2CA1NPC1 | |
| SCHEMBL244840 | 0.71 | — | — | |
| SCHEMBL24052201 | 0.71 | S1PR2 (0.37) | CA1CA12CA14 | |
| SCHEMBL8143414 | 0.70 | LMNA (0.31) | LMNAHTTSMN1; SMN2 | |
| SCHEMBL20988317 | 0.70 | LMNA (0.40) | LMNAHTTSMN1; SMN2CA1CA12 | |
| SCHEMBL22361443 | 0.70 | LMNA (0.31) | LMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797078-A4 | COMPOUNDS, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF III | ASTRAZENECA AB (SE) | 2009-04-01 | — | — | EP | claimed |
| EP-1797078-A1 | COMPOUNDS, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF III | AstraZeneca AB (SE) | 2007-06-20 | — | — | EP | claimed |
| WO-2006033630-A1 | COMPOUNDS, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF III | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | WO | claimed |
| EP-2939675-B1 | OCT3 ACTIVITY INHIBITOR CONTAINING IMIDAZOPYRIDINE DERIVATIVE AS ACTIVE COMPONENT, AND OCT3 DETECTION AGENT | SHIN NIPPON BIOMEDICAL LABORATORIES LTD (JP) | 2019-09-04 | — | — | EP | disclosed |
| US-10149840-B2 | OCT3 activity inhibitor containing imidazopyridine derivative as active component, and OCT3 detection agent | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2018-12-11 | — | — | US | disclosed |
| US-20180000797-A1 | OCT3 ACTIVITY INHIBITOR CONTAINING IMIDAZOPYRIDINE DERIVATIVE AS ACTIVE COMPONENT, AND OCT3 DETECTION AGENT | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2018-01-04 | — | — | US | disclosed |
| US-20150329540-A1 | OCT3 ACTIVITY INHIBITOR CONTAINING IMIDAZOPYRIDINE DERIVATIVE AS ACTIVE COMPONENT, AND OCT3 DETECTION AGENT | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2015-11-19 | — | — | US | disclosed |
| EP-2939675-A1 | OCT3 ACTIVITY INHIBITOR CONTAINING IMIDAZOPYRIDINE DERIVATIVE AS ACTIVE COMPONENT, AND OCT3 DETECTION AGENT | Shin Nippon Biomedical Laboratories, Ltd. (JP) | 2015-11-04 | — | — | EP | disclosed |
| EP-2210880-B1 | Benzoxazinone derivatives | MSD KK (JP) | 2015-08-26 | — | — | EP | disclosed |
| US-8314094-B2 | Benzoxazinone derivative | MSD K.K (JP) | 2012-11-20 | — | — | US | disclosed |
| EP-2448921-A1 | ARYL INDOLE DERIVATIVES | MSD K.K. (JP) | 2012-05-09 | — | — | EP | disclosed |
| WO-2007092000-A1 | INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
| EP-1798221-A1 | 2-ARYLCARBOXAMIDE-NITROGENEOUS HETEROCYCLE COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-06-20 | — | — | EP | disclosed |
| EP-1797078-A1 | COMPOUNDS, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF III | AstraZeneca AB (SE) | 2007-06-20 | — | — | EP | disclosed |
| EP-1748048-A1 | IMIDAZOPYRIDINE COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-31 | — | — | EP | disclosed |
| EP-1741703-A1 | PYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-10 | — | — | EP | disclosed |
| US-20060287340-A1 | 2-Aminoquinoline derivatives | MSD K.K. (JP) | 2006-12-21 | — | — | US | disclosed |
| EP-1657242-A1 | IMIDAZOPYRIDINE DERIVATIVES | Banyu Pharmaceutical Co., Ltd. (JP) | 2006-05-17 | — | — | EP | disclosed |
| WO-2006033630-A1 | COMPOUNDS, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF III | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | WO | disclosed |
| EP-1630162-A1 | 2-AMINOQUINOLINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10149840-B2 | OCT3 activity inhibitor containing imidazopyridine derivative as active component, and OCT3 detection agent | SLCO1B3, SLC22A8, SLCO4C1 | LMNA 3610/4885HTT 3516/4885SMN1; SMN2 4173/4885 |
| US-20060287340-A1 | 2-Aminoquinoline derivatives | MCHR2, MC2R, MCHR1 | LMNA 2760/4885HTT 729/4885SMN1; SMN2 2295/4885 |
| US-20180000797-A1 | OCT3 ACTIVITY INHIBITOR CONTAINING IMIDAZOPYRIDINE DERIVATIVE AS ACTIVE COMPONENT, AND OCT3 DETECTION AGENT | SLCO1B3, SLC22A8, SLCO4C1 | LMNA 3610/4885HTT 3516/4885SMN1; SMN2 4173/4885 |
| US-20150329540-A1 | OCT3 ACTIVITY INHIBITOR CONTAINING IMIDAZOPYRIDINE DERIVATIVE AS ACTIVE COMPONENT, AND OCT3 DETECTION AGENT | SLCO1B3, SLC22A8, SLCO4C1 | LMNA 3677/4885HTT 3353/4885SMN1; SMN2 4299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.